Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE – Get Rating) Chairman Armando Anido sold 35,453 shares of Zynerba Pharmaceuticals stock in a transaction that occurred on Monday, January 23rd. The stock was sold at an average price of $0.60, for a total transaction of $21,271.80. Following the sale, the chairman now owns 576,235 shares of the company’s stock, valued at approximately $345,741. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.
Zynerba Pharmaceuticals Stock Down 4.8 %
NASDAQ ZYNE traded down $0.03 during trading on Wednesday, reaching $0.60. 128,532 shares of the stock traded hands, compared to its average volume of 264,483. The stock’s 50-day moving average price is $0.57 and its 200 day moving average price is $0.84. Zynerba Pharmaceuticals, Inc. has a fifty-two week low of $0.49 and a fifty-two week high of $2.94.
Zynerba Pharmaceuticals (NASDAQ:ZYNE – Get Rating) last issued its quarterly earnings data on Monday, November 14th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.01. Analysts expect that Zynerba Pharmaceuticals, Inc. will post -0.86 EPS for the current year.
Institutional Inflows and Outflows
Analyst Upgrades and Downgrades
Several equities research analysts have recently commented on ZYNE shares. HC Wainwright cut shares of Zynerba Pharmaceuticals from a “buy” rating to a “neutral” rating in a research report on Tuesday, November 1st. StockNews.com upgraded shares of Zynerba Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, November 19th.
About Zynerba Pharmaceuticals
Zynerba Pharmaceuticals, Inc engages in the provision of pharmaceutically-produced transdermal cannabinoid therapies. It focuses on the research and development of rare and near-rare neuropsychiatric conditions. The firm offers the Zygel product, which is formulated as a permeation-enhanced gel for transdermal delivery.
- Get a free copy of the StockNews.com research report on Zynerba Pharmaceuticals (ZYNE)
- Is The Bottom In For Cyber-Security Stocks?
- Union Pacific, Norfolk Southern Pull into Buying Zone
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
Receive News & Ratings for Zynerba Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.